Abstract: Provided is a display device. The display device includes: a display module, having a bendable display region and a planar display region; an encapsulation housing, disposed on a non-display side of the display module, wherein a receiving chamber is formed between the encapsulation housing and the non-display side of the display module; and at least one support assembly, disposed in the receiving chamber, wherein the support assembly at least comprises a first retractable linkage and a first drive motor, a first end of the first retractable linkage is connected to the encapsulation housing, and a second end of the first retractable linkage is connected to the non-display side of the display module.

Abstract: Provided herein are pharmaceutical compositions (e.g., oral dosage formulations) comprising (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent. Also provided herein are methods of preparing and methods of using the pharmaceutical compositions.

Abstract: Provided herein are pharmaceutical compositions (e.g., oral dosage formulations) comprising (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent. Also provided herein are methods of preparing and methods of using the pharmaceutical compositions.

Abstract: Provided herein are pharmaceutical compositions (e.g., oral dosage formulations) comprising (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent. Also provided herein are methods of preparing and methods of using the pharmaceutical compositions.

Abstract: An environmental-friendly mortar robot comprises a first, second, third, and fourth container module. The first container module (2) consists of a sand midway silo, a weighing system, a stirring system, and a control system; the second container module (3) consists of a cement silo, a spiral conveying machine, a material level meter and a water storage tank; the third container module (4) consists of a fly-ash silo, a spiral conveying machine, a material level meter and an air storage tank with an air compressor; the fourth container module (5) consists of a sand storage bin, an elevator, a material level meter and an additive storage box. While transporting, the first container module can be respectively detached into four functional modules which are directly put onto a transporting vehicle together with other three container modules for transportation.

Abstract: An environmental-friendly mortar robot comprises a first, second, third, and fourth container module. The first container module (2) consists of a sand midway silo, a weighing system, a stirring system, and a control system; the second container module (3) consists of a cement silo, a spiral conveying machine, a material level meter and a water storage tank; the third container module (4) consists of a fly-ash silo, a spiral conveying machine, a material level meter and an air storage tank with an air compressor; the fourth container module (5) consists of a sand storage bin, an elevator, a material level meter and an additive storage box. While transporting, the first container module can be respectively detached into four functional modules which are directly put onto a transporting vehicle together with other three container modules for transportation.

Abstract: The present invention provides pharmaceutical compositions for intranasal delivery of a benzodiazepine. The composition may contain a therapeutically effective amount of a benzodiazepine or a pharmaceutically acceptable salt thereof, and a permeation enhancer. The permeation enhancer may be propylene glycol or a Hsieh permeation enhancer. The present compositions have excellent bioavailability. After administration of the present compositions, therapeutically effective plasma levels of the benzodiazepine may be achieved rapidly. The present pharmaceutical composition may be used to treat a patient suffering from anxiety, epilepsy, insomnia, agitation, seizures, muscular disorders, alcohol dependence, and drug withdrawal.

Abstract: The present invention provides pharmaceutical compositions for intranasal delivery of a benzodiazepine. The composition may contain a therapeutically effective amount of a benzodiazepine or a pharmaceutically acceptable salt thereof, and a permeation enhancer. The permeation enhancer may be propylene glycol or a Hsieh permeation enhancer. The present compositions have excellent bioavailability. After administration of the present compositions, therapeutically effective plasma levels of the benzodiazepine may be achieved rapidly. The present pharmaceutical composition may be used to treat a patient suffering from anxiety, epilepsy, insomnia, agitation, seizures, muscular disorders, alcohol dependence, and drug withdrawal.

Abstract: The present invention provides a preparation of a therapeutically effective amount of insulin with a concentration of A21 desamido insulin greater than about 2% (w/w).

Abstract: The present invention relates to drug delivery formulations that utilize nanocapsules, such as nanovesicles, micelles, lamellae particles, polymersomes, dendrimers, and other nano-size particles of various other fabrications, including those that are known in the art. The invention employs diblock copolymers or single block polymers that hold, adhere to, absorb or encapsulate drug molecules, including, but not limited to, those that heretofore have not been successfully formulated for oral drug delivery, e.g., insulin. Nanocapsule holding, adherence, absorption or encapsulation of such drugs or other molecules enables their delivery via oral or mucosal means.

Abstract: Compositions and methods are disclosed for treating a patient with insulin, wherein a composition in a form suitable for nasal delivery to a patient comprises a therapeutically effective amount of insulin, a permeation enhancer, a liquid carrier, and an acid present in said composition in an amount sufficient to provide an acidic pH, but not greater than a pH of 4.5, said acid being selected from the group consisting of: monovalent inorganic acid(s), sulfuric acid, and acetic acid. Preferably the composition is essentially-free of citrate(s) and essentially-free of phosphate(s). The composition being thus designed with the intent to provide a composition that is essentially-free of fibrilliform (or beta-sheet) insulin polymorphs.